Rituximab: An engineered murine/human
chimeric monoclonal antibody – granted US FDA
approval for treatment of cancer 1997
Murine-variable regions bind
specifically to CD20 on B cells
Human
κ
constant regions
Human IgG
1
Fc domain works in synergy
with human effector mechanisms